Rhumbline Advisers Summit Therapeutics Inc. Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
A detailed history of Rhumbline Advisers transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 119,808 shares of SMMT stock, worth $2.14 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
119,808
Previous 128,619
6.85%
Holding current value
$2.14 Million
Previous $1 Million
161.52%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding SMMT
# of Institutions
192Shares Held
75.8MCall Options Held
2.01MPut Options Held
2.84M-
Baker Bros. Advisors LP New York, NY24.4MShares$437 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$196 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$141 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$97.3 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$62.1 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.6B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...